MARKET

AGLE

AGLE

Aeglea Biotherap
NASDAQ
0.5200
-0.0080
-1.52%
Opening 09:39 10/05 EDT
OPEN
0.5406
PREV CLOSE
0.5280
HIGH
0.5490
LOW
0.5200
VOLUME
41.71K
TURNOVER
16.14K
52 WEEK HIGH
8.50
52 WEEK LOW
0.3720
MARKET CAP
31.81M
P/E (TTM)
-0.4125
1D
5D
1M
3M
1Y
5Y
FDA Puts Partial Hold On Aeglea's Rare Disorder Trial In Pediatric Patients
Benzinga · 1d ago
Aeglea stock dips as FDA places partial hold on enrolling under 18 patients in metabolic disorder trial
Aeglea BioTherapeutics (NASDAQ:AGLE) stock fell <font colo...
Seekingalpha · 1d ago
Aeglea BioTherapeutics Provides Clinical Progress And Regulatory Update For Homocystinuria Program
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that dosing
Benzinga · 1d ago
Aeglea BioTherapeutics Says FDA Places Partial Clinical Hold on Enrollment of Patients Under 18 in Pegtarviliase Trial
Aeglea BioTherapeutics Says FDA Places Partial Clinical Hold on Enrollment of Patients Under 18 in Pegtarviliase Trial
MT Newswires · 1d ago
Why Bed Bath & Beyond Jumped Around 25%; Here Are 68 Biggest Movers From Yesterday
Gainers
Benzinga · 08/30 09:23
Aeglea BioTherapeutics Announces Presentations At The Society For The Study Of Inborn Errors Of Metabolism On August 31
AUSTIN, Texas, Aug. 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people
Benzinga · 08/29 20:07
Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced oral and poster presentations at the Society for th...
PR Newswire · 08/29 20:05
Paltalk And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones tumbled by over 500 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 08/26 16:03
More
About AGLE
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. It is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its lead product candidate is pegzilarginase, which is a recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. It has engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. Its second product candidate, AGLE-177, is a novel PEGylated ( polyethylene glycol) human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria. The Company is evaluating Pegzilarginase in a global pivotal Phase III pivotal PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and Phase I/II open-label extension trial. It is also conducting a Phase I/II clinical trial for the treatment of patients with Homocystinuria.

Webull offers kinds of Aeglea Bio Therapeutics Inc stock information, including NASDAQ:AGLE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGLE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGLE stock methods without spending real money on the virtual paper trading platform.